Interstitial lung disease (ILD) is a risk factor for lung cancer. Patients with lung cancer associated with ILD (LC-ILD) often appear clinically. During the treatment of LC-ILD, there is a risk of causing acute exacerbation or even death in the treatment of lung cancer. At the same time, combining ILD has become the exclusion criteria for prospective clinical trials of most lung cancers. Therefore, when lung cancer is combined with ILD, it often becomes a difficult point for the treatment of lung cancer. Because LC-ILD patients have a certain proportion in the clinic, it is necessary to explore the best treatment options. Here we review the results of existing clinical studies for reference.
【中文题目：肺癌合并间质性肺炎药物治疗研究进展】 【中文摘要：间质性肺病（interstitial lung disease, ILD）是肺癌发生的危险因素，临床上经常出现肺癌合并间质性肺病（lung cancer associated with ILD, LC-ILD）患者。治疗LC-ILD过程中有导致患者ILD急剧加重甚至死亡的风险，同时合并ILD成为多数肺癌前瞻性临床试验的排除标准，因此当肺癌合并ILD时常常成为肺癌的治疗难点。由于LC-ILD患者在临床中占有一定的比例，因此有必要探寻其最佳的治疗方案。在此我们综述了现有的临床研究结果以供参考。】 【中文关键词：肺肿瘤；间质性肺炎；药物治疗】.
Keywords: Drug treatment; Interstitial pneumonia; Lung neoplasms.